NPS Pharmaceuticals PT Raised to $46.00 (NPSP)
Equities research analysts at Needham & Company increased their target price on shares of NPS Pharmaceuticals (NASDAQ:NPSP) from $28.00 to $46.00 in a research note issued to investors on Wednesday, AnalystRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Needham & Company’s price objective indicates a potential upside of 24.22% from the company’s current price.
In other NPS Pharmaceuticals news, Director Georges Gemayel sold 6,188 shares of NPS Pharmaceuticals stock on the open market in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $37.70, for a total transaction of $233,287.60. Following the completion of the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $339,300. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of NPS Pharmaceuticals (NASDAQ:NPSP) opened at 37.95 on Wednesday. NPS Pharmaceuticals has a 52-week low of $7.35 and a 52-week high of $38.74. The stock’s 50-day moving average is $35.30 and its 200-day moving average is $29.00. The company’s market cap is $3.875 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.07 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.02 by $0.05. The company had revenue of $54.45 million for the quarter, compared to the consensus estimate of $44.22 million. On average, analysts predict that NPS Pharmaceuticals will post $-0.20 earnings per share for the current fiscal year.
NPSP has been the subject of a number of other recent research reports. Analysts at Jefferies Group downgraded shares of NPS Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of NPS Pharmaceuticals in a research note on Thursday, February 6th. They now have a $34.00 price target on the stock. Finally, analysts at TheStreet upgraded shares of NPS Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, January 20th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $40.00.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a clinical-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.